Vaccines, Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food and Drug Administration
1999
FDA's Role in Bioterrorism Preparedness
publication
Evidence: moderate
Author Information
Author(s): Kathryn C. Zoon
Primary Institution: U.S. Food and Drug Administration
Hypothesis
How can the FDA enhance the development of medical products to counter bioterrorism threats?
Conclusion
The FDA is working to ensure the rapid development and approval of vaccines and treatments for bioterrorism-related threats.
Supporting Evidence
- The FDA is involved in developing new vaccines and treatments for bioterrorism threats.
- Only one licensed anthrax vaccine is currently available, which has shown 92.5% efficacy.
- The FDA is proposing to allow animal data for product approval when human trials are not feasible.
Takeaway
The FDA is trying to make sure we have vaccines and medicines ready in case of a bioterrorism attack, so people can stay safe.
Methodology
The FDA is proposing the use of animal efficacy data for product approval when human trials are not feasible.
Limitations
Human efficacy trials for bioterrorism agents are often not possible due to ethical concerns.
Statistical Information
Confidence Interval
65% to 92.5%
Want to read the original?
Access the complete publication on the publisher's website